A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of cNP8 in Healthy Adults
Latest Information Update: 18 Nov 2024
At a glance
- Drugs NMT cNP8 (Primary)
- Indications Burns
- Focus Adverse reactions; First in man
- Sponsors NeoMatrix Therapeutics
Most Recent Events
- 14 Nov 2024 Status changed from active, no longer recruiting to completed.
- 27 May 2024 Planned primary completion date changed from 1 Jul 2024 to 1 May 2024.
- 27 May 2024 Status changed from not yet recruiting to active, no longer recruiting.